Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 2
2015 1
2016 6
2017 6
2018 4
2019 8
2020 4
2021 7
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.
Farina A, Birzu C, Elsensohn MH, Picca A, Muñiz-Castrillo S, Vogrig A, Villagrán-García M, Ciano-Petersen NL, Massacesi L, Hervier B, Guégan S, Kramkimel N, Vano Y, Salem JE, Allenbach Y, Maisonobe T, Assaad S, Maureille A, Devic P, Weiss N, Pegat A, Maucort-Boulch D, Ricard D, Honnorat J, Psimaras D, Joubert B. Farina A, et al. Among authors: kramkimel n. Brain Commun. 2023 May 27;5(3):fcad169. doi: 10.1093/braincomms/fcad169. eCollection 2023. Brain Commun. 2023. PMID: 37389303 Free PMC article.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Tison A, et al. Among authors: kramkimel n. Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. doi: 10.1002/art.41068. Epub 2019 Oct 21. Arthritis Rheumatol. 2019. PMID: 31379105
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Among authors: kramkimel n. Clin Pharmacokinet. 2019 Apr;58(4):451-467. doi: 10.1007/s40262-018-0703-0. Clin Pharmacokinet. 2019. PMID: 30094711 Review.
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet JF, Rufat P, Bonnefont-Rousselot D, Batista R, Terris B, Bellanger A, Thabut D, Vozy A, Spano JP, Coriat R, Goldwasser F, Aractingi S, Sogni P, Pol S, Mallet V; CERTIM Research Group; DEMOSTHENES Research Group. Parlati L, et al. JHEP Rep. 2023 Aug 12;5(12):100880. doi: 10.1016/j.jhepr.2023.100880. eCollection 2023 Dec. JHEP Rep. 2023. PMID: 38074948 Free PMC article.
Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma.
Oberlé M, Jamme P, Mansard S, Machet L, Hervieu A, Kramkimel N, Greliak A, Jarrousse AS, Derangère V, Dudoignon D, Descarpentries C, Mortier L. Oberlé M, et al. Among authors: kramkimel n. JCO Precis Oncol. 2022 Mar;6:e2100417. doi: 10.1200/PO.21.00417. JCO Precis Oncol. 2022. PMID: 35319964 No abstract available.
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors.
Picca A, Berzero G, Bihan K, Jachiet V, Januel E, Coustans M, Cauquil C, Perrin J, Berlanga P, Kramkimel N, Garel B, Devic P, Ducray F, Benazra M, Bompaire F, Leclercq D, Michot JM, Ammari S, Psimaras D. Picca A, et al. Among authors: kramkimel n. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 26;8(3):e967. doi: 10.1212/NXI.0000000000000967. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33637598 Free PMC article.
Infliximab in recalcitrant granuloma annulare.
Amy de la Breteque M, Saussine A, Rybojad M, Kramkimel N, Vignon Pennamen MD, Bagot M, Guibal F. Amy de la Breteque M, et al. Among authors: kramkimel n. Int J Dermatol. 2016 Feb;55(2):220-2. doi: 10.1111/ijd.12458. Epub 2014 Jun 25. Int J Dermatol. 2016. PMID: 24962456 No abstract available.
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, Barnabei L, Corneau A, Da Meda L, Allayous C, Baroudjian B, Jebali M, Herms F, Grzelak L, Staropoli I, Calmettes V, Hadjadj J, Peyrony O, Cassius C, LeGoff J, Kramkimel N, Aractingi S, Fontes M, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbé C. Yatim N, et al. Among authors: kramkimel n. Sci Adv. 2021 Aug 18;7(34):eabg4081. doi: 10.1126/sciadv.abg4081. Print 2021 Aug. Sci Adv. 2021. PMID: 34407944 Free PMC article.
Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients.
Cohen E, Lheure C, Ingen-Housz-Oro S, Hotz C, Bettuzzi T, Chasset F, Descamps V, Deschamps L, Mahevas M, Terrier B, Sohier P, Guegan S, Kramkimel N, Darbord D, Chanal J, Oulès B, Aractingi S, Seta V, Dupin N. Cohen E, et al. Among authors: kramkimel n. Eur J Dermatol. 2023 Dec 1;33(6):680-685. doi: 10.1684/ejd.2023.4584. Eur J Dermatol. 2023. PMID: 38465550
42 results